Note: please keep this quiet - I don't want Harry Z to find out as it may spoil his Christmas! http://www.ncbi.nlm.nih.gov/pubmed/2115 ... t=Abstract
It would take a lot more than this information to spoil my Christmas
And it doesn't matter how quiet you are, Harry Z will hear
Tysabri has a dramatic effect on a patient's immune system so it isn't surprising that we are seeing this kind of result. Other powerful drugs (usually cancer fighting medications used on MS) also show similar kinds of results and we often hear of how those drugs have helped MS patients over a period of time. But the length of time and amount of the drug that the patient takes is often limited and there can be nasty side effects. So far, over the long haul, these drugs have little effect on the progression of the disease.
Do some patients go into a remission? Yes. Do some remain the same? Yes. Do some become worse? Yes. These kind of results have been going on for years with the various drugs and little has changed.
The biggest concern with Tysabri, as we all know, is the continually rise in risk of getting PML the longer one is on the drug. Biogen continues to tell us that the overall risk is still at 1/1000 but that has grown to double for patients on the drug over two years. So again, it boils down to benefit vs risk in choosing Tysabri or any other MS medication. At the same time, the oral drugs are becoming available but they too aren't without some side effects that increase the rate of infections. Talk about a difficult situation in trying to choose which drug to take.
It's too bad that some of the money still being spent on drug research is diverted to research on CCSVI. But that is a whole new discussion!
Have a great holiday season.